Cost-Effectiveness Analysis of Non-Statin Lipid-Modifying Agents for Secondary Cardiovascular Disease Prevention Among Statin-Treated Patients in Thailand.

Khachen KongpakwattanaZanfina AdemiThanaputt ChaiyasothiSurakit NathisuwanElla ZomerDanny LiewNathorn Chaiyakunapruk

Published in: PharmacoEconomics (2020)

Despite the proven effectiveness of PCSK9i and ezetimibe, the costs of these agents need to reduce to a much greater extent than in HICs to be cost-effective in Thailand.

Keyphrases

cardiovascular disease
newly diagnosed
end stage renal disease
ejection fraction
coronary artery disease
randomized controlled trial
type diabetes
prognostic factors
low density lipoprotein
metabolic syndrome
fatty acid